";s:4:"text";s:4531:" A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day—a double-blind comparative trial. 2001;202(3):235-8. doi: 10.1159/000051643.Pharmacoeconomics.
Amsden GW. Onychomycosis: therapeutic update.
Guest editor of the series is Babara S. Apgar, M.D., M.S., who is also an associate editor of Common dermatophyte infections. So, what does this all mean?
et al. The mycologic and clinical relapse rates were 23% and 21% in the terbinafine group, respectively, compared with 53% and 48% in the itraconazole group.
Brautigam M,
Adverse effects, including nausea, headache, pruritus and liver enzyme abnormalities, are reported in approximately 5 percent of treated patients.Fluconazole is not currently labeled by the FDA for the treatment of onychomycosis, but early efficacy data are promising.In one placebo-controlled study involving patients with fingernail onychomycosis,Treatment guidelines for the newer antifungal medications are provided in First-line therapy for dermatophytic infections (most cases of onychomycosis)250 mg per day for 6 weeks to treat fingernails and for 12 weeks to treat toenails*Complete blood count and ALT and AST levels at baseline, then every 4 to 6 weeks during therapyAlternative first-line therapy for dermatophytic infectionsContinuous therapy: 200 mg per day for 6 weeks to treat fingernails and for 12 weeks to treat toenails*ALT and AST levels at baseline, then every 4 to 6 weeks during therapyPreferred therapy for nondermatophytic and candidal infectionsPulse therapy: 200 mg twice daily for 7 days per month, with the treatment repeated for 2 to 3 months (“pulses”) to treat fingernails* and for 3 to 4 months to treat toenails†First-line therapy for candidal infections but also active against dermatophytes150 mg once weekly until nail is normal or acceptably improved (treatment often requires 6 to 9 months)†Consider for use in patients with complicated medication regimensFirst-line therapy for dermatophytic infections (most cases of onychomycosis)250 mg per day for 6 weeks to treat fingernails and for 12 weeks to treat toenails*Complete blood count and ALT and AST levels at baseline, then every 4 to 6 weeks during therapyAlternative first-line therapy for dermatophytic infectionsContinuous therapy: 200 mg per day for 6 weeks to treat fingernails and for 12 weeks to treat toenails*ALT and AST levels at baseline, then every 4 to 6 weeks during therapyPreferred therapy for nondermatophytic and candidal infectionsPulse therapy: 200 mg twice daily for 7 days per month, with the treatment repeated for 2 to 3 months (“pulses”) to treat fingernails* and for 3 to 4 months to treat toenails†First-line therapy for candidal infections but also active against dermatophytes150 mg once weekly until nail is normal or acceptably improved (treatment often requires 6 to 9 months)†Consider for use in patients with complicated medication regimensMuch of the published data on the treatment of onychomycosis are of limited clinical use. Many studies have been small and observational, and they have lacked randomization and control subjects. Evans EG. De Vroey E,
De Vroey C, Scher RK, Bieley H, Dermatol Clin 1997;15(3):535–44; Physicians' desk reference.
Montvale, N.J.: Medical Economics, 2000; and Sporanox product information update. 2018 Aug 20;4(3):99. doi: 10.3390/jof4030099.Ishita K, Stefanopoulos S, Khalil A, Cheng X, Tjarks W, Rappleye CA.Bioorg Med Chem. Evans EG. Scheys I, The oral form of ketoconazole (Nizoral) is much more effective but carries a risk of hepatotoxicity.Onychomycosis has long been treated with topical antifungal preparations. Scher RK.
Published studies have not specifically addressed the management of treatment failures or relapse.Despite these difficulties, several measures may be helpful in managing unsuccessful treatment or relapse. Scher RK. Ketoconazole Topical rated 7.0/10 vs Terbinafine rated 6.6/10 in overall patient satisfaction. However, some studies have shown terbinafine to be safe and quite effective in the treatment of tinea capitis, and it is licensed for this purpose in several countries. Gupta AK, This study ran for one year so gives a fair time span on which to assess its effectiveness. This site needs JavaScript to work properly.